Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)

NCT00485758 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

796

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus Type 2

Interventions

DRUG: ER niacin/laropiprant
DRUG: Comparator : placebo (unspecified)

Sponsor

Merck Sharp & Dohme LLC